Company Overview and News

1
TMC Life Sciences’ parent Thomson Medical inks JV with IVI-RMA Global for assisted reproductive technologies

2018-07-27 theedgemarkets - 1
KUALA LUMPUR (July 27): TMC Life Sciences Bhd said its Singaporean holding group Thomson Medical Group (TMG) has inked a joint venture (JV) agreement with IVI-RMA Global, to set up the first private assisted reproductive technologies (ART) centre in Asia.
0101

2
KLCI to trend sideways, immediate support at 1,750

2018-07-27 theedgemarkets
KUALA LUMPUR (July 27): The FBM KLCI is expected to consolidate and trend sideways against the backdrop of the mixed overnight close at most global markets, while technology-related stocks may come into focus given the massive sell-off in Facebook shares.
FB 5754 4995 0101 4405 5125 BSMAF 5212 1818

 
Tan Chong Motor, Utusan, Versatile Creative, Pantech, TMC Life, Pavilion REIT, ViTrox, Ajiya, Ancom and Tasek Corp

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): Based on corporate announcements and news flow today, companies that may be in focus on Friday (July 27) may include the following: Tan Chong Motor Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative, Pantech Group Holdings Bhd, TMC Life Sciences Bhd, Pavilion Real Estate Investment Trust, ViTrox Corp Bhd, Ajiya Bhd, Ancom Bhd and Tasek Corp Bhd
5754 4995 0101 5016 4405 5125 BSMAF 5212 1818

 
TMC Life Sciences 3Q net profit down 5.5% on higher opex

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): TMC Life Sciences Bhd's net profit for the third quarter ended May 31, 2018 fell 5.5% to RM5.63 million, from RM5.96 million a year earlier, due to higher operating expenditure that was incurred to strengthen the group's human capital.
0101 BSMAF 1818

 
KLCI to trend higher, immediate hurdle at 1,755

2018-07-18 theedgemarkets
KUALA LUMPUR (July 19): The FBM KLCI is expected to trend higher today, tracking the overnight gains at most global markets, with immediate hurdle at 1,755 points.
7073 0101 5062 6459 5272 5268 7200

 
Maxis, Seacera, Sapura Energy, MNRB, TMC Life Sciences, Ranhill, Hua Yang, Ikhmas Jaya, Menang Corp and Tek Seng

2018-07-18 theedgemarkets
KUALA LUMPUR (July 18): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 19) may include the following: Maxis Bhd, Seacera Group Bhd, Sapura Energy Bhd, MNRB Holdings Bhd, TMC Life Sciences Bhd, Ranhill Holdings Bhd, Hua Yang Bhd, Ikhmas Jaya Group Bhd, Menang Corp (M) Bhd and Tek Seng Holdings Bhd.
7073 0101 5062 6459 5272 BSMAF 5268 7200 1818

 
TMC Life Sciences looks to double revenue by 2020

2018-07-18 theedgemarkets
PETALING JAYA (July 18): TMC Life Sciences Bhd, which is controlled by Singaporean billionaire Peter Lim Eng Hock, is looking to double its revenue by 2020, driven by expansion of its rebranded Thomson Hospital Kota Damansara (THKD), which was formerly known as the Tropicana Medical Centre.
0101

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to MYX:0101 / TMC LIFE SCIENCES BERHAD on message board site Silicon Investor.

0101_ Japan Mutual Fund 0101_ Japan Mutual Fund 0101_ Japan Mutual Fund